Although many chemotherapy agents and regimens have been studied and used as adjuvant chemotherapy in patients with high-risk, early-stage, HR-positive breast cancer, anthracycline- and taxane-based chemotherapy regimens proved to be the most active in this setting. Taxane-based, anthracycline-free regimens can be also considered, in particular for low-risk tumors.
Combination chemotherapy regimens are standard for patients with early-stage breast cancer, whereas single-agent treatment is not recommended.
The combination of a platinum agent plus an antifolate, such as cisplatin and pemetrexed, is often used to treat non–small-cell lung cancer but is not one of the preferred options for early breast cancer.
The patient works full time in customer service for an auto insurance company and is raising two young teenage sons. She is very concerned about preventing disease recurrence and extending overall survival.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Stefania Morganti. Skill Checkup: A 51-Year-Old Woman With a 3 cm Lump in the Upper Right Quadrant of Right Breast - Medscape - Dec 19, 2022.